Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by zeus55on Sep 03, 2013 9:28pm

132 Views

Post# 21716280

RE:ZEUS55 Please share with us all your predictions of what the outcome maybe over the next 5-10 trading days

trussell, you claim to have access to insider knowledge, and you expect us to believe you wouldn't trade with that info?
Then after-the-fact, you claim to have known what was coming today, but didn't post it because people would have given you grief?
Give me a friggin break.

Bullboard Posts

Eminent acquires promising Nevada gold project